Geodon (Ziprasidone) for Posttraumatic Stress Disorder

Completed · Phase 4

Conditions studied: Posttraumatic Stress Disorder, Post-Traumatic Stress Disorder, PTSD

In brief

Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).

Key facts

Study ID
NCT00208208
Run by
Creighton University
People needed
80
Starts
2002-12-01
Expected to finish
2005-04-01
Last updated by the study team
2006-09-15

Who can join

Age: 19 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.